Sequana Medical - First patient enrolled in MOJAVE, interim results in Q4
Sequana announced that a first patient, part of the 1st 3-patient non-randomized cohort has been enrolled in MOJAVE with DSR 2.0. Based on the results from these 3 patients, foreseen in Q4 23, the company expects to receive approval from the Data and Safety Monitoring Board to start the enrollment of the randomized cohort, including 30 patients. This news was expected as Sequana announced last week that the first patient would be enrolled imminently. Given the early stage of the program development and the limited visibility on DSR 2.0 efficacy profile, we currently allocate a 35% success rate to theSequana Medical NV. Sequana Medical NV is a Belgium-based company, which manufactures medical devices. The Company focuses mainly on the development of treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders. Sequana Medical NV provides alfapump, which is an implantable, programmable, wireless-charged and battery-powered system that is CE-marking for the management of refractory ascites due to liver cirrhosis and malignant ascites. Over 650 alfapump systems have been implanted. Apart from the Alfapump, the Company also aims to develop a direct sodium removal (DSR) therapy, which is a propriety approach to the treatment of volume overload in heart failure.
We are an investment house with Belgian roots founded on more than 150 years of trust.
As a private company owned by long-term committed shareholders, we are independent. Naturally and structurally. Our experts have the knowledge to think and act without bias, and to make decisions that benefit our clients. Today and tomorrow.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.